From professional translators, enterprises, web pages and freely available translation repositories.
rasagilin
rasagiline
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
virkestoff er rasagilin.
the active substance is rasagiline.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
azilect 1 mg tabletter rasagilin
azilect 1 mg tablets rasagiline
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
rasagilin var signifikant bedre enn placebo.
rasagiline produced statistically significant benefit compared to placebo.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
absolutt biotilgjengelighet av en enkeltdose rasagilin er 36%.
the absolute bioavailability of a single rasagiline dose is about 36%.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
det er ikke kjent om rasagilin skilles ut i morsmelk.
it is not known whether rasagiline is excreted in human milk.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
rasagilin bør unngås hos pasienter med moderat nedsatt leverfunksjon.
rasagiline use in patients with moderate hepatic impairment should be avoided.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
i parentes angis bivirkningsfrekvens (%) for rasagilin mot placebo, respektivt.
in parentheses is the adverse reaction incidence (% of patients) in rasagiline vs. placebo, respectively.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
irreversible, selektive mao-b-hemmere (selegilin, rasagilin)
irreversible, selective mao-b inhibitor (selegiline, rasagiline)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
det har vært rapporter om hypotensive effekter når rasagilin tas samtidig med levodopa.
there have been reports of hypotensive effects when rasagiline is taken concomitantly with levodopa.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
eksperimentelle data indikerer at rasagilin hemmer prolaktinsekresjon og derfor kan hemme melkeproduksjonen.
experimental data indicated that rasagiline inhibits prolactin secretion and thus, may inhibit lactation.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
det bør gå minst 5 uker fra seponering av fluoksetin og til behandling med rasagilin påbegynnes.
at least five weeks should elapse between discontinuation of fluoxetine and initiation of treatment with rasagiline.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forsiktighet bør utvises når en starter behandling med rasagilin hos pasienter med lett nedsatt leverfunksjon.
caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
etter markedsføring er disse symptomene også observert hos parkinson-pasienter behandlet med rasagilin.
in post marketing experience, these symptoms have also been observed in parkinson's disease patients treated with rasagiline.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
rasagilin viste ikke gentoksisk potensiale in vivo og i flere in vitro systemer med bakterier og leverceller.
rasagiline did not present genotoxic potential in vivo and in several in vitro systems using bacteria or hepatocytes.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
det bør gå minst 14 dager mellom seponering av rasagilin og til behandling med fluoksetin eller fluvoksamin påbegynnes.
at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with fluoxetine or fluvoxamine.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
absorpsjon: rasagilin absorberes raskt, og når maks plasmakonsentrasjon (cmax) i løpet av ca..
absorption: rasagiline is rapidly absorbed, reaching peak plasma concentration (cmax) in approximately
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
det må gå minst 14 dager mellom seponering av rasagilin og til behandling med mao-hemmere eller petidin påbegynnes.
at least 14 days must elapse between discontinuation of rasagiline and initiation of treatment with mao inhibitors or pethidine.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
effekten av rasagilin er vist i tre studier: som monoterapi i studie i og som tilleggsbehandling til levodopa i studiene ii og iii.
the efficacy of rasagiline was established in three studies: as monotherapy treatment in study i and as adjunct therapy to levodopa in the studies ii and iii.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
rasagilin er en potent, irreversibel selektiv mao-b-hemmer som kan gi økt ekstracellulært nivå av dopamin i striatum.
rasagiline was shown to be a potent, irreversible mao-b selective inhibitor, which may cause an increase in extracellular levels of dopamine in the striatum.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: